UK Markets closed

Valneva SE (INRLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
13.60-0.44 (-3.17%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close14.05
Open13.60
BidN/A x N/A
AskN/A x N/A
Day's range13.60 - 13.60
52-week range4.50 - 18.55
Volume100
Avg. volume3,634
Market cap1.37B
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)-1.31
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Valneva Appoints Peter Buhler as Chief Financial Officer

    Saint-Herblain (France), July 29, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced the appointment of Peter Buhler as Chief Financial Officer (CFO) and Management Board member. Peter has over 20 years of experience in the strategic and financial leadership of life science and technology companies. He currently ser

  • Globe Newswire

    Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate

    Saint-Herblain (France) and New York, NY, July 19, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. (NYSE: PFE), today announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial builds on previous positive Phase 2 trials and includes both ad

  • Globe Newswire

    Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate

    This new U.S. Milestone Follows FDA Fast Track and EMA PRIME Designations Saint Herblain (France), July 7, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the U.S. Food and Drug Administration (FDA).